EyeCRO scientists contribute to study published in Experimental Eye Research
Intravitreal administration of small molecule read-through agents demonstrate functional activity in a nonsense mutation mouse model.
Similar Posts
Patient-reported outcomes and visual acuity after 12 months of anti-VEGF-treatment for sight-threatening diabetic macular edema in a real world setting
This study was an evaluation, at 12 months follow-up, of anti VEGF treatment for diabetic macular edema conducted in a real world setting. To examine objective visual acuity measured with ETDRS, retinal thickness (OCT), patient reported outcome and describe levels of glycated hemoglobin and its association with the effects on visual acuity in patients treated…
New Polymer Allows Improved Method for Preparation of Nanoparticles for Drug Delivery
Ainhoa Lejardi, an engineer at the UPV/EHU, has created a new polymer material which could improve the preparation of nanospheres for their use as a method of controlling the release of pharmaceuticals, research which is currently ongoing at the Consejo Superior de Investigaciones Científicas (CSIC) (Spanish National Research Council) in Madrid. http://www.azonano.com/news.aspx?newsID=24876
InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids
Inmed Pharmaceuticals Inc. (NASD: INM) has secured a worldwide license to formulate any cannabinoid molecule using MiDROPS® for ophthalmic instillation. Click here to read the full press release.
Double-Barreled Biologic for Diabetic Retinopathy Emerging
CHICAGO — Investigators searching for new ways to manage diabetic macular edema are targeting pathways beyond vascular endothelial growth factor (VEGF). Phase 2 results from the BOULEVARD trial (NCT02699450), which is comparing faricimab, the first biologic to target both the Ang-2 and VEGF pathways, with ranibizumab, will be presented at the American Society of Retina Specialists (ASRS) 2019 Annual…
Aerie Pharmaceuticals Announces Potential Breakthroughs with New Preclinical Research
Aerie Pharmaceuticals, Inc. (AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today potentially breakthrough findings from new preclinical research. The research found that RhopressaTM suppressed the activity of profibrotic proteins – TGF-beta 2 and…